A Phase 1, Open-label, Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of INCB028060 in Subjects With Advanced Malignancies.
Phase of Trial: Phase I
Latest Information Update: 24 Nov 2017
At a glance
- Drugs Capmatinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Incyte Corporation
- 10 Jun 2017 Biomarkers information updated
- 14 Feb 2013 Status changed from active, no longer recruiting to completed, according to an Incyte Corporation media release.
- 09 Nov 2012 Planned End Date changed from 1 Jun 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.